Bridgefront Capital’s Intellia Therapeutics NTLA Stock Holding History

Bridgefront Capital’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$199K	Sell	11,774 -6,756	-36%	-$94.6K	0.05%	457
2026 Q1	$238K	Buy	+18,530	New	+$236K	0.06%	444
2025 Q1	–	Sell	-24,521	Closed	-$286K	–	785
2024 Q4	$286K	Buy	24,521 +9,932	+68%	+$155K	0.1%	375
2024 Q3	$300K	Buy	14,589 +5,292	+57%	+$122K	0.12%	315
2024 Q2	$208K	Buy	+9,297	New	+$221K	0.09%	405
2021 Q1	–	Sell	-4,334	Closed	-$236K	–	843
2020 Q4	$236K	Buy	+4,334	New	+$157K	0.08%	460

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Bridgefront Capital's NTLA Position: Q2 2026 in Review

Bridgefront Capital reduced its Intellia Therapeutics (NTLA) stake by 36% in Q2 2026, selling an estimated $94.6K and leaving 11,774 shares worth $199K. The position accounts for 0.05% of the portfolio, ranked #457.

Bridgefront Capital first reported a position in NTLA in Q4 2020 and has held it in 6 quarters since. The position peaked at $300K in Q3 2024. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Bridgefront Capital held 11,774 shares of Intellia Therapeutics worth $199K as of Q2 2026.
Bridgefront Capital sold 6,756 Intellia Therapeutics shares in Q2 2026, an estimated $94.6K.
Intellia Therapeutics made up 0.05% of Bridgefront Capital's portfolio in Q2 2026, its #457 holding.
Bridgefront Capital first reported a position in Intellia Therapeutics in Q4 2020 and has held it in 6 quarters since.
Bridgefront Capital's Intellia Therapeutics position peaked at $300K in Q3 2024.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.